<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB05137</drugbank-id>
  <name>Lobeline</name>
  <description>An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]</description>
  <cas-number>90-69-7</cas-number>
  <unii>D0P25S3P81</unii>
  <average-mass>337.4553</average-mass>
  <monoisotopic-mass>337.204179113</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3259</ref-id>
        <pubmed-id>17368966</pubmed-id>
        <citation>Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, Kracke GR: Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend. 2007 Jul 10;89(2-3):282-91. Epub 2007 Mar 21.</citation>
      </article>
      <article>
        <ref-id>A3260</ref-id>
        <pubmed-id>16825297</pubmed-id>
        <citation>Wu J, Liu Q, Yu K, Hu J, Kuo YP, Segerberg M, St John PA, Lukas RJ: Roles of nicotinic acetylcholine receptor beta subunits in function of human alpha4-containing nicotinic receptors. J Physiol. 2006 Oct 1;576(Pt 1):103-18. Epub 2006 Jul 6.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in addictions.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Lobeline inhibits nicotine-evoked dopamine release and [3H]nicotine binding, thus acting as a potent antagonist at both alpha3beta2(*) and alpha4beta2(*) neuronal nicotinic receptor subtypes. However, lobeline does not release dopamine from its presynaptic terminal, but appears to induce the metabolism of dopamine intraneuronally. Reevaluation of the mechanism by which lobeline alters dopamine function reveals that its primary mechanism is inhibition of dopamine uptake and promotion of dopamine release from the storage vesicles within the presynaptic terminal, via an interaction with the tetrabenazine-binding site on the vesicular monoamine transporter (VMAT2). Thus, lobeline appears to perturb the fundamental mechanisms of dopamine storage and release. Based on its neurochemical mechanism, the ability of lobeline to functionally antagonize the neurochemical and behavioral effects of the psychostimulants amphetamine and methamphetamine was examined. Lobeline was found to inhibit the amphetamine-induced release of dopamine in vitro, and amphetamine-induced hyperactivity, drug discrimination, and self-administration.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.</description>
    <direct-parent>Alkyl-phenylketones</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic oxygen compounds</superclass>
    <class>Organooxygen compounds</class>
    <subclass>Carbonyl compounds</subclass>
    <alternative-parent>1,3-aminoalcohols</alternative-parent>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Aromatic alcohols</alternative-parent>
    <alternative-parent>Aryl alkyl ketones</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Beta-amino ketones</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Piperidines</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>1,3-aminoalcohol</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Alkyl-phenylketone</substituent>
    <substituent>Amine</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic alcohol</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Aryl alkyl ketone</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Beta-aminoketone</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Piperidine</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="inn">Lobelina</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alkaloids</category>
      <mesh-id>D000470</mesh-id>
    </category>
    <category>
      <category>Autonomic Agents</category>
      <mesh-id>D001337</mesh-id>
    </category>
    <category>
      <category>Cholinergic Agents</category>
      <mesh-id>D018678</mesh-id>
    </category>
    <category>
      <category>Cholinergic Agonists</category>
      <mesh-id>D018679</mesh-id>
    </category>
    <category>
      <category>Ganglionic Stimulants</category>
      <mesh-id>D005731</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Nicotinic Agonists</category>
      <mesh-id>D018722</mesh-id>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Piperidines</category>
      <mesh-id>D010880</mesh-id>
    </category>
    <category>
      <category>Respiratory System Agents</category>
      <mesh-id>D019141</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>4afh</pdb-entry>
    <pdb-entry>5afh</pdb-entry>
    <pdb-entry>5afj</pdb-entry>
    <pdb-entry>5afk</pdb-entry>
    <pdb-entry>5afl</pdb-entry>
    <pdb-entry>5afm</pdb-entry>
    <pdb-entry>5afn</pdb-entry>
    <pdb-entry>5oug</pdb-entry>
    <pdb-entry>5ouh</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The risk or severity of adverse effects can be increased when Esmolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The risk or severity of adverse effects can be increased when Betaxolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The risk or severity of adverse effects can be increased when Metoprolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The risk or severity of adverse effects can be increased when Atenolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The risk or severity of adverse effects can be increased when Timolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of adverse effects can be increased when Sotalol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The risk or severity of adverse effects can be increased when Propranolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The risk or severity of adverse effects can be increased when Labetalol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The risk or severity of adverse effects can be increased when Bisoprolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The risk or severity of adverse effects can be increased when Alprenolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The risk or severity of adverse effects can be increased when Pindolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The risk or severity of adverse effects can be increased when Carvedilol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The risk or severity of adverse effects can be increased when Propafenone is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of adverse effects can be increased when Acebutolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The risk or severity of adverse effects can be increased when Nadolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The risk or severity of adverse effects can be increased when Bevantolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The risk or severity of adverse effects can be increased when Practolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The risk or severity of adverse effects can be increased when Penbutolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The risk or severity of adverse effects can be increased when Dexpropranolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The risk or severity of adverse effects can be increased when Celiprolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The risk or severity of adverse effects can be increased when Nebivolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The risk or severity of adverse effects can be increased when Bufuralol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>The risk or severity of adverse effects can be increased when Bopindolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The risk or severity of adverse effects can be increased when Bupranolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The risk or severity of adverse effects can be increased when Indenolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>The risk or severity of adverse effects can be increased when Befunolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The risk or severity of adverse effects can be increased when Arotinolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The risk or severity of adverse effects can be increased when Talinolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The risk or severity of adverse effects can be increased when Anisodamine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The risk or severity of adverse effects can be increased when Landiolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The risk or severity of adverse effects can be increased when Bucindolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The risk or severity of adverse effects can be increased when Esatenolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The risk or severity of adverse effects can be increased when Cloranolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>The risk or severity of adverse effects can be increased when Mepindolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The risk or severity of adverse effects can be increased when Epanolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>The risk or severity of adverse effects can be increased when Tertatolol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09271</drugbank-id>
      <name>Cimetropium</name>
      <description>Lobeline may decrease the anticholinergic activities of Cimetropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The risk or severity of adverse effects can be increased when Pegvisomant is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The risk or severity of adverse effects can be increased when Ramipril is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The risk or severity of adverse effects can be increased when Mefloquine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The risk or severity of adverse effects can be increased when Tacrine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The risk or severity of adverse effects can be increased when Sulpiride is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The risk or severity of adverse effects can be increased when Profenamine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of adverse effects can be increased when Triflupromazine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The risk or severity of adverse effects can be increased when Cisplatin is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00527</drugbank-id>
      <name>Cinchocaine</name>
      <description>The risk or severity of adverse effects can be increased when Cinchocaine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00545</drugbank-id>
      <name>Pyridostigmine</name>
      <description>The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The risk or severity of adverse effects can be increased when Nizatidine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>The risk or severity of adverse effects can be increased when Galantamine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00677</drugbank-id>
      <name>Isoflurophate</name>
      <description>The risk or severity of adverse effects can be increased when Isoflurophate is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00711</drugbank-id>
      <name>Diethylcarbamazine</name>
      <description>The risk or severity of adverse effects can be increased when Diethylcarbamazine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of adverse effects can be increased when Procaine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The risk or severity of adverse effects can be increased when Perindopril is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The risk or severity of adverse effects can be increased when Minaprine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of adverse effects can be increased when Terbutaline is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The risk or severity of adverse effects can be increased when Hexafluronium is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00944</drugbank-id>
      <name>Demecarium</name>
      <description>The risk or severity of adverse effects can be increased when Demecarium is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00981</drugbank-id>
      <name>Physostigmine</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00989</drugbank-id>
      <name>Rivastigmine</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01010</drugbank-id>
      <name>Edrophonium</name>
      <description>The risk or severity of adverse effects can be increased when Edrophonium is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of adverse effects can be increased when Procainamide is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>The risk or severity of adverse effects can be increased when Memantine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01122</drugbank-id>
      <name>Ambenonium</name>
      <description>The risk or severity of adverse effects can be increased when Ambenonium is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The risk or severity of adverse effects can be increased when Tubocurarine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The risk or severity of adverse effects can be increased when Ketamine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Decamethonium is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The risk or severity of adverse effects can be increased when Pancuronium is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Pipecuronium is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01381</drugbank-id>
      <name>Ginkgo biloba</name>
      <description>The risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The risk or severity of adverse effects can be increased when Neostigmine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>The risk or severity of adverse effects can be increased when Bambuterol is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02365</drugbank-id>
      <name>1,10-Phenanthroline</name>
      <description>The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The risk or severity of adverse effects can be increased when Thiotepa is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04864</drugbank-id>
      <name>Huperzine A</name>
      <description>The risk or severity of adverse effects can be increased when Huperzine A is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04892</drugbank-id>
      <name>Phenserine</name>
      <description>The risk or severity of adverse effects can be increased when Phenserine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05386</drugbank-id>
      <name>Regramostim</name>
      <description>The risk or severity of adverse effects can be increased when Regramostim is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06756</drugbank-id>
      <name>Glycine betaine</name>
      <description>The risk or severity of adverse effects can be increased when Glycine betaine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The risk or severity of adverse effects can be increased when Capsaicin is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11390</drugbank-id>
      <name>Coumaphos</name>
      <description>The risk or severity of adverse effects can be increased when Coumaphos is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11397</drugbank-id>
      <name>Dichlorvos</name>
      <description>The risk or severity of adverse effects can be increased when Dichlorvos is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11412</drugbank-id>
      <name>Fenthion</name>
      <description>The risk or severity of adverse effects can be increased when Fenthion is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11473</drugbank-id>
      <name>Metrifonate</name>
      <description>The risk or severity of adverse effects can be increased when Metrifonate is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12482</drugbank-id>
      <name>Acotiamide</name>
      <description>The risk or severity of adverse effects can be increased when Acotiamide is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13058</drugbank-id>
      <name>Methanesulfonyl Fluoride</name>
      <description>The risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13495</drugbank-id>
      <name>Paraoxon</name>
      <description>The risk or severity of adverse effects can be increased when Paraoxon is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13503</drugbank-id>
      <name>Tyrothricin</name>
      <description>The risk or severity of adverse effects can be increased when Tyrothricin is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13668</drugbank-id>
      <name>Ipidacrine</name>
      <description>The risk or severity of adverse effects can be increased when Ipidacrine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13694</drugbank-id>
      <name>Distigmine</name>
      <description>The risk or severity of adverse effects can be increased when Distigmine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14031</drugbank-id>
      <name>Tretamine</name>
      <description>The risk or severity of adverse effects can be increased when Tretamine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15317</drugbank-id>
      <name>Posiphen</name>
      <description>The risk or severity of adverse effects can be increased when Posiphen is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02845</drugbank-id>
      <name>Methylphosphinic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Methylphosphinic Acid is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Capreomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Framycetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Amikacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Tobramycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Gentamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Netilmicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Neomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Streptomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Kanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Paromomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Ribostamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Geneticin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Apramycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Gentamicin C1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Neamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Arbekacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Puromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Dihydrostreptomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Hygromycin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Sisomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Plazomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Dibekacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Micronomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Isepamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>The therapeutic efficacy of Lobeline can be decreased when used in combination with Bekanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The risk or severity of adverse effects can be increased when Donepezil is combined with Lobeline.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.73</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.98e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>2-[(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethan-1-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(-)-lobeline</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>337.4553</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>337.204179113</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CN1[C@H](C[C@H](O)C2=CC=CC=C2)CCC[C@@H]1CC(=O)C1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C22H27NO2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>MXYUKLILVYORSK-HBMCJLEFSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>40.54</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>101.51</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>39.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>14.42</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>130.5 Â°C</value>
      <source>PhysProp</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>48723</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>101616</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175426951</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07475</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02364</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>91814</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50080818</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>L0B</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Lobeline</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL122270</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0002343</id>
      <name>Neuronal acetylcholine receptor subunit alpha-9</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UGM1" source="Swiss-Prot">
        <name>Neuronal acetylcholine receptor subunit alpha-9</name>
        <general-function>Calcium channel activity</general-function>
        <specific-function>Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane (PubMed:11752216, PubMed:25282151). In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma. May also regulate keratinocyte adhesion (PubMed:11021840).</specific-function>
        <gene-name>CHRNA9</gene-name>
        <locus>4p14</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>238-262
269-287
302-323
458-476</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>6.42</theoretical-pi>
        <molecular-weight>54806.63</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:14079</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRNA9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ243342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>6688136</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>469</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>469</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UGM1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACHA9_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NACHR alpha-9</synonym>
          <synonym>NACHRA9</synonym>
          <synonym>Nicotinic acetylcholine receptor subunit alpha-9</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011683|Neuronal acetylcholine receptor subunit alpha-9
MNWSHSCISFCWIYFAASRLRAAETADGKYAQKLFNDLFEDYSNALRPVEDTDKVLNVTL
QITLSQIKDMDERNQILTAYLWIRQIWHDAYLTWDRDQYDGLDSIRIPSDLVWRPDIVLY
NKADDESSEPVNTNVVLRYDGLITWDAPAITKSSCVVDVTYFPFDNQQCNLTFGSWTYNG
NQVDIFNALDSGDLSDFIEDVEWEVHGMPAVKNVISYGCCSEPYPDVTFTLLLKRRSSFY
IVNLLIPCVLISFLAPLSFYLPAASGEKVSLGVTILLAMTVFQLMVAEIMPASENVPLIG
KYYIATMALITASTALTIMVMNIHFCGAEARPVPHWARVVILKYMSRVLFVYDVGESCLS
PHHSRERDHLTKVYSKLPESNLKAARNKDLSRKKDMNKRLKNDLGCQGKNPQEAESYCAQ
YKVLTRNIEYIAKCLKDHKATNSKGSEWKKVAKVIDRFFMWIFFIMVFVMTILIIARAD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011684|Neuronal acetylcholine receptor subunit alpha-9 (CHRNA9)
ATGAACTGGTCCCATTCCTGCATCTCCTTTTGCTGGATCTACTTTGCTGCTTCCAGACTG
AGAGCTGCAGAGACGGCAGATGGAAAATATGCTCAGAAGTTGTTTAATGACCTTTTTGAA
GATTATTCTAATGCTCTTCGTCCAGTGGAAGATACAGATAAAGTCCTGAATGTGACCCTG
CAGATTACGCTCTCTCAGATTAAGGATATGGATGAAAGAAACCAAATTCTGACTGCTTAT
TTGTGGATCCGCCAAATCTGGCACGATGCCTATCTCACGTGGGACCGAGATCAGTACGAT
GGCCTAGACTCCATCAGGATCCCCAGTGACCTCGTGTGGAGGCCAGACATCGTCTTATAT
AACAAGGCTGATGATGAATCTTCAGAGCCTGTGAACACCAATGTGGTCCTGCGGTATGAT
GGGCTGATCACCTGGGATGCACCGGCCATCACCAAAAGCTCCTGTGTGGTGGATGTCACC
TACTTCCCTTTTGACAACCAGCAGTGCAACCTGACTTTTGGTTCCTGGACCTACAATGGC
AATCAGGTGGACATATTCAACGCCTTGGACAGCGGAGATCTCTCTGACTTCATTGAAGAT
GTGGAATGGGAGGTCCATGGCATGCCCGCTGTGAAGAATGTGATCTCCTATGGCTGCTGC
TCTGAGCCTTACCCGGATGTCACATTCACCCTCCTTCTGAAGAGGAGGTCCTCGTTCTAT
ATCGTCAACCTCCTCATCCCATGCGTCCTCATATCTTTTCTGGCTCCTCTGAGTTTTTAT
CTCCCAGCAGCCTCCGGAGAAAAGGTCTCCCTGGGAGTGACCATCCTGTTGGCCATGACT
GTATTTCAGCTAATGGTGGCAGAAATCATGCCGGCCTCAGAAAATGTGCCCCTGATAGGT
AAATACTACATAGCCACGATGGCCCTGATCACAGCCTCCACTGCGTTGACCATCATGGTG
ATGAATATCCACTTCTGTGGGGCCGAGGCCCGGCCGGTGCCACACTGGGCCAGGGTGGTC
ATCCTGAAATACATGTCCAGGGTCTTGTTTGTCTATGATGTGGGTGAAAGCTGCCTCAGC
CCGCACCACAGTAGAGAGCGGGACCACCTCACGAAAGTTTATAGCAAACTCCCAGAGTCT
AACCTGAAAGCAGCCAGGAACAAAGACCTTTCCAGAAAGAAGGACATGAACAAACGCTTA
AAGAACGACCTGGGCTGCCAGGGTAAGAACCCTCAGGAGGCCGAGAGTTACTGTGCACAG
TACAAAGTGCTGACGAGGAATATTGAGTACATCGCCAAGTGCCTCAAAGACCACAAGGCC
ACCAATTCCAAGGGGAGTGAATGGAAGAAGGTGGCGAAAGTCATAGACCGATTCTTCATG
TGGATTTTTTTCATTATGGTGTTTGTGATGACTATTTTGATCATAGCAAGAGCGGATTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-gated cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of mechanical stimulus involved in sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inner ear morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000411</id>
      <name>Neuronal acetylcholine receptor subunit alpha-10</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9GZZ6" source="Swiss-Prot">
        <name>Neuronal acetylcholine receptor subunit alpha-10</name>
        <general-function>Receptor binding</general-function>
        <specific-function>Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma.</specific-function>
        <gene-name>CHRNA10</gene-name>
        <locus>11p15.5</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>238-258
268-288
302-322
429-449</transmembrane-regions>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi>7.97</theoretical-pi>
        <molecular-weight>49704.295</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:13800</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRNA10</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ278118</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>12053839</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>470</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>470</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9GZZ6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACH10_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NACHR alpha-10</synonym>
          <synonym>NACHRA10</synonym>
          <synonym>Nicotinic acetylcholine receptor subunit alpha-10</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010285|Neuronal acetylcholine receptor subunit alpha-10
MGLRSHHLSLGLLLLFLLPAECLGAEGRLALKLFRDLFANYTSALRPVADTDQTLNVTLE
VTLSQIIDMDERNQVLTLYLWIRQEWTDAYLRWDPNAYGGLDAIRIPSSLVWRPDIVLYN
KADAQPPGSASTNVVLRHDGAVRWDAPAITRSSCRVDVAAFPFDAQHCGLTFGSWTHGGH
QLDVRPRGAAASLADFVENVEWRVLGMPARRRVLTYGCCSEPYPDVTFTLLLRRRAAAYV
CNLLLPCVLISLLAPLAFHLPADSGEKVSLGVTVLLALTVFQLLLAESMPPAESVPLIGK
YYMATMTMVTFSTALTILIMNLHYCGPSVRPVPAWARALLLGHLARGLCVRERGEPCGQS
RPPELSPSPQSPEGGAGPPAGPCHEPRCLCRQEALLHHVATIANTFRSHRAAQRCHEDWK
RLARVMDRFFLAIFFSMALVMSLLVLVQAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010286|Neuronal acetylcholine receptor subunit alpha-10 (CHRNA10)
ATGCCGGCGCGGCGGCGCGTGCTCACCTACGGCTGCTGCTCCGAGCCCTACCCCGACGTC
ACCTTCACGCTGCTGCTGCGCCGCCGCGCCGCCGCCTACGTGTGCAACCTGCTGCTGCCC
TGCGTGCTCATCTCGCTGCTTGCGCCGCTCGCCTTCCACCTGCCTGCCGACTCAGGCGAG
AAGGTGTCGCTGGGCGTCACCGTGCTGCTGGCGCTCACCGTCTTCCAGTTGCTGCTGGCC
GAGAGCATGCCACCGGCCGAGAGCGTGCCGCTCATCGGGAAGTACTACATGGCCACTATG
ACCATGGTCACATTCTCAACAGCACTCACCATCCTTATCATGAACCTGCATTACTGTGGT
CCCAGTGTCCGCCCAGTGCCAGCCTGGGCTAGGGCCCTCCTGCTGGGACACCTGGCACGG
GGCCTGTGCGTGCGGGAAAGAGGGGAGCCCTGTGGGCAGTCCAGGCCACCTGAGTTATCT
CCTAGCCCCCAGTCGCCTGAAGGAGGGGCTGGCCCCCCAGCGGGCCCTTGCCACGAGCCA
CGATGTCTGTGCCGCCAGGAAGCCCTACTGCACCACGTAGCCACCATTGCCAATACCTTC
CGCAGCCACCGAGCTGCCCAGCGCTGCCATGAGGACTGGAAGCGCCTGGCCCGTGTGATG
GACCGCTTCTTCCTGGCCATCTTCTTCTCCATGGCCCTGGTCATGAGCCTCCTGGTGCTG
GTGCAGGCCCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of mechanical stimulus involved in sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inner ear morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="1">
      <id>BE0002341</id>
      <name>Neuronal acetylcholine receptor subunit alpha-7</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19798</ref-id>
            <pubmed-id>9833639</pubmed-id>
            <citation>Briggs CA, McKenna DG: Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neuropharmacology. 1998 Sep;37(9):1095-102.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P36544" source="Swiss-Prot">
        <name>Neuronal acetylcholine receptor subunit alpha-7</name>
        <general-function>Toxic substance binding</general-function>
        <specific-function>After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.</specific-function>
        <gene-name>CHRNA7</gene-name>
        <locus>15q14</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>231-255
262-280
296-317
470-490</transmembrane-regions>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi>6.44</theoretical-pi>
        <molecular-weight>56448.925</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1960</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRNA7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X70297</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>496607</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>468</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>468</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P36544</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACHA7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NACHRA7</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004597|Neuronal acetylcholine receptor subunit alpha-7
MRCSPGGVWLALAASLLHVSLQGEFQRKLYKELVKNYNPLERPVANDSQPLTVYFSLSLL
QIMDVDEKNQVLTTNIWLQMSWTDHYLQWNVSEYPGVKTVRFPDGQIWKPDILLYNSADE
RFDATFHTNVLVNSSGHCQYLPPGIFKSSCYIDVRWFPFDVQHCKLKFGSWSYGGWSLDL
QMQEADISGYIPNGEWDLVGIPGKRSERFYECCKEPYPDVTFTVTMRRRTLYYGLNLLIP
CVLISALALLVFLLPADSGEKISLGITVLLSLTVFMLLVAEIMPATSDSVPLIAQYFAST
MIIVGLSVVVTVIVLQYHHHDPDGGKMPKWTRVILLNWCAWFLRMKRPGEDKVRPACQHK
QRRCSLASVEMSAVAPPPASNGNLLYIGFRGLDGVHCVPTPDSGVVCGRMACSPTHDEHL
LHGGQPPEGDPDLAKILEEVRYIANRFRCQDESEAVCSEWKFAACVVDRLCLMAFSVFTI
ICTIGILMSAPNFVEAVSKDFA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020606|Neuronal acetylcholine receptor subunit alpha-7 (CHRNA7)
ATGCGCTGCTCGCCGGGAGGCGTCTGGCTGGCGCTGGCCGCGTCGCTCCTGCACGTGTCC
CTGCAAGGCGAGTTCCAGAGGAAGCTTTACAAGGAGCTGGTCAAGAACTACAATCCCTTG
GAGAGGCCCGTGGCCAATGACTCGCAACCACTCACCGTCTACTTCTCCCTGAGCCTCCTG
CAGATCATGGACGTGGATGAGAAGAACCAAGTTTTAACCACCAACATTTGGCTGCAAATG
TCTTGGACAGATCACTATTTACAGTGGAATGTGTCAGAATATCCAGGGGTGAAGACTGTT
CGTTTCCCAGATGGCCAGATTTGGAAACCAGACATTCTTCTCTATAACAGTGCTGATGAG
CGCTTTGACGCCACATTCCACACTAACGTGTTGGTGAATTCTTCTGGGCATTGCCAGTAC
CTGCCTCCAGGCATATTCAAGAGTTCCTGCTACATCGATGTACGCTGGTTTCCCTTTGAT
GTGCAGCACTGCAAACTGAAGTTTGGGTCCTGGTCTTACGGAGGCTGGTCCTTGGATCTG
CAGATGCAGGAGGCAGATATCAGTGGCTATATCCCCAATGGAGAATGGGACCTAGTGGGA
ATCCCCGGCAAGAGGAGTGAAAGGTTCTATGAGTGCTGCAAAGAGCCCTACCCCGATGTC
ACCTTCACAGTGACCATGCGCCGCAGGACGCTCTACTATGGCCTCAACCTGCTGATCCCC
TGTGTGCTCATCTCCGCCCTCGCCCTGCTGGTGTTCCTGCTTCCTGCAGATTCCGGGGAG
AAGATTTCCCTGGGGATAACAGTCTTACTCTCTCTTACCGTCTTCATGCTGCTCGTGGCT
GAGATCATGCCCGCAACATCCGATTCGGTACCATTGATAGCCCAGTACTTCGCCAGCACC
ATGATCATCGTGGGCCTCTCGGTGGTGGTGACAGTGATCGTGCTGCAGTACCACCACCAC
GACCCCGACGGGGGCAAGATGCCCAAGTGGACCAGAGTCATCCTTCTGAACTGGTGCGCG
TGGTTCCTGCGAATGAAGAGGCCCGGGGAGGACAAGGTGCGCCCGGCCTGCCAGCACAAG
CAGCGGCGCTGCAGCCTGGCCAGTGTGGAGATGAGCGCCGTGGCGCCGCCGCCCGCCAGC
AACGGGAACCTGCTGTACATCGGCTTCCGCGGCCTGGACGGCGTGCACTGTGTCCCGACC
CCCGACTCTGGGGTAGTGTGTGGCCGCATGGCCTGCTCCCCCACGCACGATGAGCACCTC
CTGCACGGCGGGCAACCCCCCGAGGGGGACCCGGACTTGGCCAAGATCCTGGAGGAGGTC
CGCTACATTGCCAACCGCTTCCGCTGCCAGGACGAAAGCGAGGCGGTCTGCAGCGAGTGG
AAGTTCGCCGCCTGTGTGGTGGACCGCCTGTGCCTCATGGCCTTCTCGGTCTTCACCATC
ATCTGCACCATCGGCATCCTGATGTCGGCTCCCAACTTCGTGGAGGCCGTGTCCAAAGAC
TTTGCGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axolemma</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic shaft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>growth cone</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>presynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-gated cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-amyloid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxic substance binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>associative learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cognition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>generation of ovulation cycle rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-1 beta production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-6 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuronal action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of heart rate involved in baroreceptor response to decreased systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to food</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sperm motility</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell activation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>